Diminished b-globin synthesis in b-thalassemia is associated with ineffective erythropoiesis, leading to secondary iron overload caused by inappropriately low levels of hepcidin and to splenomegaly in the symptomatic thalassemias. Splenectomy is often employed in patients with b-thalassemia to reduce hemolysis. Expression of the iron regulatory peptide hormone hepcidin is repressed by the serine protease TMPRSS6. Hepcidin induction by RNAi-mediated inhibition of erythropoiesis. 5, 6 In either case, the resulting secondary iron overload in each subset of the disease may lead to organ damage in the liver, heart, and endocrine system, which can be managed, often sub optimally, with chelation therapy. Another complication associated with 
| I N TR ODU C TI ON
A growing number of mutations in the b-globin gene, or in its upstream regulatory elements, 1 cause diminished or complete lack of protein synthesis. The resulting a-globin imbalance causes precipitates that adhere to the cell membrane, leading to premature destruction of erythroid precursors, and an increase in radical oxygen species, red blood cell (RBC) damage and decreased RBC half-life. erythropoiesis. 5, 6 In either case, the resulting secondary iron overload in each subset of the disease may lead to organ damage in the liver, heart, and endocrine system, which can be managed, often sub optimally, with chelation therapy. Another complication associated with b-thalassemia is splenomegaly due to extramedullary hematopoiesis and increased turnover of senescent/damaged RBCs. Splenectomy may be indicated for thalassemia patients with recurrent splenic infarction, right upper quadrant pain, early satiety, or to reduce the risk of splenic rupture. 7 Splenectomy may also be required under conditions of rapidly increasing transfusion demand or hypersplenism to increase RBC survival. 8 It has been suggested that splenectomy is specifically indicated when there is an increase of 50% or more in the red cell transfusion requirement over a one-year period.
9
TMPRSS6, also known as matriptase-2, is a membrane-bound serine protease 10 expressed in hepatocytes that negatively modulates 
| M E TH ODS
All mouse strains and methods are identical to those previously 
| Synthesis of GalNAc-conjugated siRNAs
GalNAc-Tmprss6 is a subcutaneously administered siRNA formulation based on a previously described duplex targeting Tmprss6.
25,28
GalNAc-Con is identical to GalNAc-Tmprss6 except that it was chemically modified at position 2 of the antisense strand to prevent RNAimediated cleavage of the target mRNA. 29 3 | RE S U L TS 3.1 | RNAi-mediated reduction of Tmprss6 by GalNAc-Tmprss6
The conjugation of siRNA to N-acetylgalactosamine (GalNAc) has recently been described. 28, 30, 31 These conjugates specifically target the asialoglycoprotein (ASGPR), also known as the Ashwell-Morell, receptor. 32 Specifically expressed in hepatocytes, this receptor binds to terminal galactose or GalNAc glycans and is rapidly endocytosed. 33 siRNA trivalent-GalNAc conjugates are highly stable in vivo, can be We modulated hepcidin expression in vivo by targeting Tmprss6 with a GalNAc-formulated Tmprss6 siRNA (GalNAc-Tmprss6). We compared WT C57BL/6J mice injected with GalNAc-Tmprss6 or a PBS control. We found that treatment with increasing concentrations of GalNAc-Tmprss6 diminished Tmprss6 mRNA ( Figure 1A ) and reciprocally increased hepcidin protein in a dose-dependent manner ( Figure   1B ), resulting in decreased transferrin saturation ( Figure 1C) . Furthermore, to confirm the suitability of a GalNAc-siRNA-control (GalNAcCon) we injected mice with 0.3 mg/kg of PBS, GalNAc-Con, or
GalNAc-Tmprss6 and measured Tmprss6 mRNA after 14 days ( Figure   1D ). We found that the GalNAc-siRNA-control did not reduce Tmprss6
mRNA. These data demonstrate that GalNAc-Tmprss6 siRNA conjugate can effectively target Tmprss6, leading to a sustained increase in hepcidin expression and a concomitant decrease in transferrin saturation.
| Silencing of Tmprss6 with GalNAc-Tmprss6 upregulates hepcidin and diminishes secondary iron overload in murine b-thalassemia
To assess the efficacy of limiting iron in splenectomized b-thalassemia patients, we sought to modulate hepcidin expression in vivo by target- 
| GalNAc-Tmprss6 siRNA improves erythropoiesis in splenectomized murine b-thalassemia intermedia
Unlike in humans, splenectomy in murine b-thalassemia intermedia mice results in a reduction in the baseline hemoglobin accompanied by a reduction in reticulocytes that is almost half that seen in untreated splenectomized Hbb th3/1 animals (data not shown). 18, 25 This is likely due to the fact that the spleen is a normal site of erythropoiesis in the adult mouse. 36 Nonetheless, treatment of splenectomized Hbb th3/1 mice improves their anemia ( Figure 3A ) as a consequence of increased RBC numbers ( Figure 3B ) even in the setting of diminished cellular hemoglobin of the reticulocyte (CHr, Figure 3C ) and mean cell hemoglobin (MCH, data not shown). Interestingly, the mean cell volume (MCV, Figure 3D ) remains unchanged in treated Hbb th3/1 animals lacking a spleen; our previous studies 18,25 demonstrated a pronounced decrease in MCV in siRNA treated animals. This may be secondary to loss of the spleen's normal "conditioning" of the RBC membrane which results in loss of membrane and a reduction in the MCV; it is not due to an increase in reticulocytes, as, following treatment, the reticulocyte fraction ( Figure 3E ) and the absolute number of reticulocytes ( Figure   3F ) are decreased. Combined with the diminished reticulocytosis, a reduced serum erythropoietin ( Figure 3G ) suggests an overall decrease in erythroid drive. The improvement in erythropoiesis is readily appreciated on peripheral blood smears, which demonstrate replacement of the polychromasia and anisopoikilocytosis of the baseline phenotype with a relatively normal population of evenly sized and shaped hypochromic RBC's ( Figure 2H ).
| D I SCUSSION
We previously demonstrated that RNAi-mediated reduction of hepatic These studies demonstrate that this effect is independent of the spleen, and is consistent with the hypothesis that system iron restriction resulting from hepcidin induction likely modulates ineffective erythropoiesis directly during red cell formation and not due to alterations in red cell recycling. This validates the concept that increasing hepcidin expression and diminishing total body iron burden through RNAi mediated Tmprss6 reduction may be an effective treatment in b-thalassemia patients that have previously undergone splenectomy.
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